Anti-amyloid monoclonal antibodies for the treatment of Alzheimer's disease
J Cummings, AML Osse, D Cammann, J Powell… - BioDrugs, 2024 - Springer
Two monoclonal antibodies (mAbs), aducanumab and lecanemab, have received
accelerated approval from the US FDA for initiation of treatment in early Alzheimer's disease …
accelerated approval from the US FDA for initiation of treatment in early Alzheimer's disease …
Biomarker-based staging of Alzheimer disease: rationale and clinical applications
J Therriault, SE Schindler, G Salvadó… - Nature Reviews …, 2024 - nature.com
Disease staging, whereby the spatial extent and load of brain pathology are used to
estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard …
estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard …
Data-driven modelling of neurodegenerative disease progression: thinking outside the black box
Data-driven disease progression models are an emerging set of computational tools that
reconstruct disease timelines for long-term chronic diseases, providing unique insights into …
reconstruct disease timelines for long-term chronic diseases, providing unique insights into …
Disease staging of Alzheimer's disease using a CSF-based biomarker model
G Salvadó, K Horie, NR Barthélemy, JW Vogel… - Nature aging, 2024 - nature.com
Biological staging of individuals with Alzheimer's disease (AD) may improve diagnostic and
prognostic workup of dementia in clinical practice and the design of clinical trials. In this …
prognostic workup of dementia in clinical practice and the design of clinical trials. In this …
New precision medicine avenues to the prevention of Alzheimer's disease from insights into the structure and function of γ-secretases
B De Strooper, E Karran - The EMBO Journal, 2024 - embopress.org
Two phase-III clinical trials with anti-amyloid peptide antibodies have met their primary goal,
ie slowing of Alzheimer's disease (AD) progression. However, antibody therapy may not be …
ie slowing of Alzheimer's disease (AD) progression. However, antibody therapy may not be …
Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease
Recent longitudinal PET imaging studies have established methods to estimate the age at
which amyloid becomes abnormal at the level of the individual. Here we recontextualized …
which amyloid becomes abnormal at the level of the individual. Here we recontextualized …
A one-two punch targeting reactive oxygen species and fibril for rescuing Alzheimer's disease
J Wang, P Shangguan, X Chen, Y Zhong, M Lin… - Nature …, 2024 - nature.com
Toxic amyloid-beta (Aβ) plaque and harmful inflammation are two leading symptoms of
Alzheimer's disease (AD). However, precise AD therapy is unrealizable due to the lack of …
Alzheimer's disease (AD). However, precise AD therapy is unrealizable due to the lack of …
[HTML][HTML] Alzheimer's disease puzzle: delving into pathogenesis hypotheses
Alzheimer's disease (AD) is a prevalent neurodegenerative disease characterized by both
amnestic and non-amnestic clinical manifestations. It accounts for approximately 60-70% of …
amnestic and non-amnestic clinical manifestations. It accounts for approximately 60-70% of …
[HTML][HTML] Amyloid induced hyperexcitability in default mode network drives medial temporal hyperactivity and early tau accumulation
In early Alzheimer's disease (AD) β-amyloid (Aβ) deposits throughout association cortex and
tau appears in the entorhinal cortex (EC). Why these initially appear in disparate locations is …
tau appears in the entorhinal cortex (EC). Why these initially appear in disparate locations is …
OCT Imaging in Murine Models of Alzheimer's Disease in a Systematic Review: Findings, Methodology and Future Perspectives
The murine models of Alzheimer's disease (AD) have advanced our understanding of the
pathophysiology. In vivo studies of the retina using optical coherence tomography (OCT) …
pathophysiology. In vivo studies of the retina using optical coherence tomography (OCT) …